Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03623776
Other study ID # GASTO1038
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date February 1, 2019
Est. completion date March 1, 2024

Study information

Verified date March 2019
Source Sun Yat-sen University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

JS001 (Toripalimab) is a recombinant humanized anti-PD-1 monoclonal antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2. The purpose of this study is to studying neoadjuvant JS001, or JS001 in combination with pemetrexed and carboplatin to see how well it works in treating patients with resectable NSCLC.


Description:

Surgery in combination with preoperative or postoperative chemotherapy is the recommended therapeutic approach for patients with resectable non-small cell lung cancer (NSCLC). However, the prognosis of early-stage NSCLC remains to be improved, with 5-year survival rates ranging from 50% for stage IA to 20% for stage IIIA. Antibodies that block the PD-1 protein have provided a major treatment advance in patients with cancer. JS001 (Toripalimab) is a recombinant humanized anti-PD-1 monoclonal antibody, which has shown its efficacy in the treatment of a variety of malignancies. This study is to studying neoadjuvant JS001, or JS001 in combination with chemotherapy to see how well it works in treating patients with resectable NSCLC.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 80
Est. completion date March 1, 2024
Est. primary completion date March 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Target population is high risk NSCLC with resection option for potential cure, as assessed by a faculty surgeon at SYSUCC. This may include clinical stage IB (=4cm), II and IIIA. Subjects with N3 nodal involvement are not included.

- Subjects should not have a previously detected sensitizing EGFR mutation or ALK fusion oncogene.

- Written informed consent provided.

- Male and female patients aged =18 years, < 75 years.

- Able to comply with the required protocol and follow-up procedures, and able to receive oral medications.

- Blood and specimens before and after treatment must be provided

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

- Life expectancy =12 weeks.

- Adequate hematological function: Absolute neutrophil count (ANC) =2.0 x 109/L, and Platelet count =100 x 109/L, and Hemoglobin =9 g/dL (may be transfused to maintain or exceed this level).

- Adequate liver function: Total bilirubin = 1.5 x upper limit of normal (ULN), Aspartate aminotransferase (AST), alanine aminotransferase (ALT) = 2.5 x ULN in subjects without liver metastases; = 5 x ULN in subjects with liver metastases.

- Adequate renal function: Serum creatinine = 1.25 x ULN, or = 60 ml/min.

- Female subjects should not be pregnant or breast-feeding.

Exclusion Criteria:

- Known severe hypersensitivity to JS001 or any of the excipients of this product.

- Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody (including any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).

- Prior chemotherapy or radiotherapy.

- Subjects with active, known or suspected autoimmune disease. Subjects in conditions not expected to recur in the absence of an external trigger, or not requiring systemic treatment are permitted to enroll.

- Subjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first administration of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.

- Inability to comply with protocol or study procedures.

- A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study.

- A serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease.

- History of another malignancy in the last 5 years with the exception of the following: other malignancies cured by surgery alone and having a continuous disease-free interval of 5 years are permitted. Cured basal cell carcinoma of the skin and cured in situ carcinoma of the uterine cervix are permitted.

- Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).

- Patient who has active serious infection (e.g. pyrexia of or 38.0? over)

- Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).

- Known history of active Hepatitis B or C.

- Women who are pregnant or nursing.

- Evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding giving reasonable suspicion of a disease or condition that contraindicated the use of an investigational drug or puts the subject at high risk for treatment-related complications.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
JS001
JS001 was given 240 mg i.v. infusion on Day 1 of each 21-day cycle for 3 cycles.
Pemetrexed
Subjects receive pemetrexed of 500 mg/m^2 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
Carboplatin
Subjects receive carboplatin at the AUC of 5 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
Procedure:
Thoracic Surgery
Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.

Locations

Country Name City State
China Sun Yat-sen University Cancer Center Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary 3-year Disease Free Survival Disease-free survival was assessed from registration to disease recurrence or death as a result of any cause. 3 years after the last patient is registered
Secondary Number of participants with treatment-related adverse events (AEs) Adverse Events were monitored according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. 2 years after the last patient is registered
Secondary Number of participants with perioperative complications Perioperative complications will be recorded 2 years
Secondary 3-year Overall survival Overall survival was assessed from registration to death as a result of any cause. 3 years after the last patient is registered
Secondary Pathologic Response To assess pathologic response to neoadjuvant JS001, or JS001 in combination with chemotherapy in resected tumor and lymph nodes. Major pathologic response was defined as <10% residual viable tumor cells in the resection specimen. 3 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04759534 - Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia Phase 3
Not yet recruiting NCT05532111 - Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial N/A
Active, not recruiting NCT04284215 - Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLC N/A
Completed NCT06202456 - A Phase IV Study of Huazhi Rougan Granule in the Treatment of Non-alcoholic Simple Fatty Liver Phase 4
Completed NCT04870606 - Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness Phase 3
Completed NCT03660761 - Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors Phase 2
Active, not recruiting NCT03794778 - Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer Phase 4
Recruiting NCT03255343 - Treatment of Non-responding to Conventional Therapy Inoperable Liver Cancers by in Situ Introduction of ImDendrim N/A
Recruiting NCT04197544 - Evaluation of the Implantation of the End-vascular Creation of the Arteriovenous Fistulas in Patients in the University Hospital of Araba. Pilot Study. N/A
Recruiting NCT04518501 - Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer Phase 1/Phase 2
Completed NCT03779776 - The Efficacy and Safety of Early Vitamin AD Supplementation in Very Preterm Infants N/A
Not yet recruiting NCT06218004 - Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma Phase 2
Enrolling by invitation NCT02809079 - Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Phase 4
Active, not recruiting NCT06194188 - A Phase 2 Clinical Study of CU-20401 Phase 2
Recruiting NCT03901235 - MSC Intratissular Injection in Crohn Disease Patients Phase 1/Phase 2
Completed NCT03826004 - Clemastine in Cardiovascular Surgery N/A
Recruiting NCT04078399 - Efficacy and Safety of Azacitidine Combined With Interferon in the Treatment of Post-transplant Recurrence N/A
Not yet recruiting NCT06351735 - Efficacy and Safety of Deep Cervical Lymph Node-vein Bypass Surgery in ALS Amyotrophic Lateral Sclerosis
Not yet recruiting NCT06383078 - HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer Phase 2
Withdrawn NCT05481775 - Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer Phase 2